Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 1/2014

01-02-2014 | short review

Development of treatment and clinical results in childhood acute myeloid leukemia in Slovenia in the period from 1991 to 2010

Authors: Orjana Velikonja, MD, Milica Stefanović, MD, Asst. Lidija Kitanovski, MSc, MD, Assist. prof. Helena Podgornik, PhD, Assist. prof. Janez Jazbec, PhD, MD

Published in: memo - Magazine of European Medical Oncology | Issue 1/2014

Login to get access

Abstract

Background

A review of treatment and survival of children with acute myeloid leukemia (AML) in Slovenia from 1991 to 2010.

Methods

We collected demographic data, information on the time, and course of treatment of patients with AML, which were classified in three risk groups and treated according to standard arm of BFM AML protocols 83, 93, 98, and 04. We assessed the rate of remission, event-free survival and overall survival, the incidence of relapse, the secondary neoplasms, secondary AML, the proportion of patients treated with hematopoietic stem cell transplantation (HSCT) and causes of death. The 2- and 5-year overall survival (5yOS) was estimated according to age group, risk group, the presence of remission, and the time of the treatment.

Results

There were 50 patients, 18 males (36 %) and 32 females (64 %) included in this study. Secondary AML was presented in four patients. Patients treated with HSCT were 18 (36 %), 9 of them in first remission. The 2-year overall survival (2yOS) was 63.7 ± 6.8 % and 5-year survival was 55.0 ± 7.2 %. Differences in survival between age groups (0–5 years, 6–10 years and more than 10 years) was not significant. All patients in standard risk group lived for more than 2 years, in high-risk group 2yOS was 56.7 ± 7.7 % (p = 0.05). Patients who were in remission before second treatment block had 2yOS 77.8 ± 7.4 % and 5yOS 63.8 ± 8.8 %, compared to the patients who were not in remission (2yOSand 5yOS 37.5 ± 12.1 %, p = 0.001). The 2yOS in patients treated with HSCT in first remission was 62 %. There were 17 patients (34 %) who had relapse of the disease, 23 (64 %) patients died, 14 (61 %) due to progression of the disease.

Conclusions

The results of treatment of AML in our center are comparable with other European centers. Survival was better in the standard risk group and in patients who were in remission before second treatment block. We observed a trend of improvement in survival in the time observed.
Literature
1.
Ching-Hong P. Childhood leukemias. Cambridge University Press; 2006.
2.
World health organization—Europe. Incidence of childhood leukemia. Fact sheet 4.1, December 2009, Code: RPG4_Rad_E1.
3.
Avcin S, Prelog T, Kavcic M, Kitanovski L, Anzic J, Benedik Dolnicar M, Rajic V, Zadravec Zaletel L, Debeljak M, Jazbec J. History of treatment and long-term outcome of childhood acute lymphoblastic leukemia in Slovenia. MEMO. 2011;4:178–83.CrossRef
4.
Tsukimoto I, Tawa A, Horibe K, Tabuchi K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 Trial From the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27:4007–13.PubMedCrossRef
5.
Reinhardt D. Kooperative AML-BFM Therapiestudien [Internet]. Hannover: Medizinische Hochschule Hannover, Klinik und Poliklinik für Kinderheilkunde, Pädiatrische Hämatologie/ Onkologie; c 2005–2013 [cited 2013 May 7]. Available at: http://​aml.​mh-hannover.​de/​
6.
Woods WG. Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep. Pediatr Blood Cancer. 46:565–9.
7.
Rubnitz J, Gibson B, Smith F. Acute myeloid leukemia. Hematol Oncol Clin North Am. 2010;24:35–63.PubMedCrossRef
8.
Smith M, Gloeckler Ries L, Gurney J, Ross J. Leukemia. SEER Pediatric Monograph, National Cancer Institute: 17–34.
9.
Razzouk BI, Estey E, Pounds S, Lensing S, Pierce S, Brandt M, et al. Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions. Cancer. 2006;106(11):2495–502PubMedCrossRef
10.
Rubnitz JE, Lensing S, Zhou Y, Sandlund JT, Razzouk BI, Ribeiro RC, et al. Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer. 2004;101(7):1677–84.PubMedCrossRef
11.
Creutzig U, Büchner T, Sauerland MC, Zimmermann M, Reinhardt D, Döhner H, et al. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer. 2008;112:562–71.PubMedCrossRef
12.
Schoch C, Kern W, Schnittger S, Büchner T, Hiddemann W, Torsten H. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica. 2004;89:1082–90.PubMed
13.
Horibe K, Tsukimoto I, Ohno R. Clinicopathologic characteristics of leukemia in Japanese children and young adults. Leukemia. 2001;15:1256–61.PubMedCrossRef
14.
Barnard DR, Lange B, Alonzo TA, Buckley J, Kobrinsky JN, Gold S, et al. Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. Blood. 2002;100:427–34.PubMedCrossRef
15.
Ravindranath Y. Down syndrome and leukemia: new insights into the epidemiology, pathogenesis, and treatment. Pediatr Blood Cancer. 2005;44:1–7 (Commentary).PubMedCrossRef
16.
Hasle H, Niemeyer CM. Advances in the prognostication and management of advanced MDS in children. Br J Haematol. 2011;154:185–95.PubMedCrossRef
17.
Tilak V, Sookmane DD, Gupta V, Shukla J. Myelodysplastic syndrome. Indian J Pediatr. 2008;75(7):729–32.PubMedCrossRef
18.
Abrahamsson J, Forestier E, Heldrup J, Jahnukainen K, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol. 2011;29:310–15.PubMedCrossRef
19.
Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19:2030–42.PubMedCrossRef
20.
Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24:4499–506.PubMedCrossRef
21.
Kern W, Haferlach T, Schoch C, Löffler H, Gassmann W, Heinecke A, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
22.
Niewerth D, Creutzig C, Bierings MB, Kaspers GJL. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood. 2010;116:2205–14.PubMedCrossRef
23.
Mlakar U. Treatment of acute myeloid leukemia in adults in the period 2008–2011 at the university medical centre Ljubljana. Zdr.Vest. 2012;Supp. II:21–6.
24.
Harrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom medical research council treatment trials AML 10 and 12. J Clin Oncol. 2010;28(16):2674–81.PubMedCrossRef
25.
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of tumors of hematopoietic and lymphoid tissues, 4th Edn. Geneva: WHO Press; 2008.
Metadata
Title
Development of treatment and clinical results in childhood acute myeloid leukemia in Slovenia in the period from 1991 to 2010
Authors
Orjana Velikonja, MD
Milica Stefanović, MD
Asst. Lidija Kitanovski, MSc, MD
Assist. prof. Helena Podgornik, PhD
Assist. prof. Janez Jazbec, PhD, MD
Publication date
01-02-2014
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 1/2014
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0090-z

Other articles of this Issue 1/2014

memo - Magazine of European Medical Oncology 1/2014 Go to the issue

editorial

The importance of HPV vaccination today

original report

Development of treatment and clinical results in childhood AML in Austria (1993–2013)

short review

Wild-type GIST: a comprehensive review

short review

Breast cancer surveillance: nothing has changed in the past decades (?)

short review

Treatment and clinical results in childhood AML in Greece

short review

Anthracycline cardiotoxicity and lymphoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits